<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235870</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-1100-0013</org_study_id>
    <nct_id>NCT02235870</nct_id>
  </id_info>
  <brief_title>Obalon Balloon System Pivotal IDE (SMART) Trial</brief_title>
  <acronym>SMART</acronym>
  <official_title>The Six-Month Adjunctive Weight Reduction Therapy (SMART) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obalon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Obalon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pivotal trial of the Obalon Balloon System is intended to generate safety and
      effectiveness data required to support a future marketing application. The trial has been
      designed to evaluate a 6-month use of the Obalon Balloon System as an adjunct to a nutrition
      and lifestyle behavior modification program.

      Weight loss will be evaluated after the 6-month course to determine if a specific predefined
      superiority margin can be achieved in the device group compared to a sham-control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)</measure>
    <time_frame>6 months</time_frame>
    <description>Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%</description>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Subjects With at Least 5% Total Body Loss: Obalon - Sham Group</measure>
    <time_frame>6 Months</time_frame>
    <description>Difference in percentage of subjects between the Obalon Treatment and Sham Control groups with at least 5% Total Body Loss (TBL)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">711</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Obalon Intragastric Balloons</intervention_name>
    <description>Intragastric Balloon System to aid in portion control.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Device</intervention_name>
    <description>Sham Intragastric Balloon</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutrition and Lifestyle Program</intervention_name>
    <description>Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between the ages of 22-64 years

          2. Current BMI of 30.0 - 40 kg/m2

          3. Previously attempted to lose weight unsuccessfully using a medically supervised or
             non-medically supervised diet

          4. Willing to attend all protocol-specified follow-up visits plus any additional
             follow-up visits as required throughout the entire study period

          5. Willing to avoid non-commercial air travel and scuba diving during the entire study
             period

          6. Willing to avoid medications or other substances known to effect weight changes during
             the study

          7. Willing to avoid Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other medications
             known to be gastric irritants during the study

          8. Willing to use contraception and avoid pregnancy during the study if the subject is
             female with child bearing potential

          9. Willing to provide written informed consent

        Exclusion Criteria:

          1. Significant weight loss in the past 12 months

          2. Use of medications or other substances known to induce weight gain or weight loss

          3. Participation in any clinical study at the start of this trial or in the last year

          4. Known history of endocrine disorders affecting weight

          5. Currently receiving chronic steroid or immunosuppressive therapy or has previously
             been diagnosed with HIV

          6. Subjects diagnosed with bulimia, binge eating, compulsive overeating, high liquid
             calorie intake habits or similar eating related psychological disorders

          7. Intent to undergo gastric surgery or gastric banding during the study period or within
             the 6 month period after completion of this study

          8. Prior use of any weight loss medical device

          9. Known history of structural or functional disorders of the esophagus

         10. Known history of structural or functional disorder of the esophagus, including any
             swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal
             reflux symptoms

         11. Known history of structural or functional disorders of the stomach

         12. Known history of a structural or functional disorder of the stomach, including any
             symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic
             dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or
             pain, post-prandial nausea or vomiting or early satiety

         13. Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal
             varices, intestinal stricture/stenosis, small bowel obstruction, or any other
             obstructive disorder of the gastrointestinal (GI) tract

         14. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction,
             such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting

         15. Known history irritable bowel syndrome, radiation enteritis or other inflammatory
             bowel disease, such as Crohn's disease

         16. Known history of GI surgeries that may have resulted in anatomical GI tract
             abnormalities

         17. Type 1 diabetes

         18. Type 2 diabetes requiring insulin or other hypoglycemic oral agents.

         19. Experienced a myocardial infarction, has a known history of angina, a known history of
             congestive heart failure, or is currently being medically treated for any other
             cardiac condition

         20. Poorly controlled hypertension, (≥ 160 mmHg Systolic and ≥ 100mmHg Diastolic).

         21. End stage renal disease or requiring hemodialysis within the past 6 months

         22. Unwilling or unable to avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including
             Aspirin, Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric
             irritants beginning two weeks prior to enrollment and throughout the entire study
             period

         23. Subjects taking medications on specified hourly intervals that may be affected by
             changes to gastric emptying

         24. Subjects requiring the use of anti-platelet drugs or other agents affecting the normal
             clotting of blood

         25. Untreated or unstable alcohol or illicit drug addiction

         26. Known history of allergies to any component of the device materials

         27. Currently pregnant or breastfeeding or intention of becoming pregnant during the study

         28. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical
             condition, in the opinion of the investigator

         29. Subject is employed by the investigator, or is a close relative of the investigator,
             or the investigator's staff

         30. Subject is a close relative of another subject already enrolled in the study.

         31. Any other condition that, in the opinion of the investigator, would interfere with
             subject participation, may confound the study results, or interfere with compliance
             with the study (e.g., psychosocial issues).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy VandenBerg</last_name>
    <role>Study Chair</role>
    <affiliation>Obalon Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bariatric Institute of Greater Chicago</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopic Microsurgery Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Hospital in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Bariatrics</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midsouth Bariatrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <results_first_submitted>June 28, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2018</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight Loss</keyword>
  <keyword>Obesity</keyword>
  <keyword>BMI</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>711 subjects signed an informed consent form to participate in the study and proceeded to the screening eligibility process</recruitment_details>
      <pre_assignment_details>430 subjects randomized in a Treatment or Control group, 387 subjects received an Obalon Balloon or Sham Device.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obalon Treatment Group</title>
          <description>Obalon Balloon Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sham Control Group</title>
          <description>Sham Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Phase I (Week 24)</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Crossover (Week 24)</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obalon Treatment Group</title>
          <description>Obalon Balloon Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sham Control Group</title>
          <description>Sham Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="189"/>
            <count group_id="B3" value="387"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="9.6"/>
                    <measurement group_id="B2" value="42.5" spread="9.3"/>
                    <measurement group_id="B3" value="42.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="2.7"/>
                    <measurement group_id="B2" value="35.5" spread="2.7"/>
                    <measurement group_id="B3" value="35.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups</title>
        <description>Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per Protocol cohort which includes subjects with at least 2 devices for at least 18 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Obalon Treatment Group</title>
            <description>Obalon Balloon Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sham Control Group</title>
            <description>Sham Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups</title>
          <description>Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin</description>
          <population>Per Protocol cohort which includes subjects with at least 2 devices for at least 18 weeks</population>
          <units>%TBL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="0.37"/>
                    <measurement group_id="O2" value="3.59" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0261</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Square Mean Difference</param_type>
            <param_value>3.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.24</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)</title>
        <description>Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%</description>
        <time_frame>6 months</time_frame>
        <population>Per Protocol cohort which includes subjects in the Obalon Treatment group with at least 2 balloons for at least 18 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Obalon Treatment Group</title>
            <description>Subjects who received the Obalon Balloons.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)</title>
          <description>Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%</description>
          <population>Per Protocol cohort which includes subjects in the Obalon Treatment group with at least 2 balloons for at least 18 weeks</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Subjects in the Obalon Treatment group with at least 2 Balloons and balloon therapy for at least 18 weeks.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact Test</method>
            <param_type>Exact Confidence Interval</param_type>
            <param_value>64.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.5</ci_lower_limit>
            <ci_upper_limit>71.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects With at Least 5% Total Body Loss: Obalon - Sham Group</title>
        <description>Difference in percentage of subjects between the Obalon Treatment and Sham Control groups with at least 5% Total Body Loss (TBL)</description>
        <time_frame>6 Months</time_frame>
        <population>Per Protocol cohort which includes subjects with at least 2 devices for at least 18 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Obalon Treatment Group</title>
            <description>Obalon Balloon Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sham Control Group</title>
            <description>Sham Device with Weight Loss Behavior Modification (WLBM) Program for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 5% Total Body Loss: Obalon - Sham Group</title>
          <description>Difference in percentage of subjects between the Obalon Treatment and Sham Control groups with at least 5% Total Body Loss (TBL)</description>
          <population>Per Protocol cohort which includes subjects with at least 2 devices for at least 18 weeks</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <param_type>Percentage Difference</param_type>
            <param_value>32.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.1</ci_lower_limit>
            <ci_upper_limit>42.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated Subjects</title>
          <description>Treated subjects include the 198 subjects in Phase I of the study who received at least 1 Obalon Balloon and the 138 subjects in Phase II who crossover and received at least 1 Obalon Balloon</description>
        </group>
        <group group_id="E2">
          <title>Control Subjects</title>
          <description>Control subjects include the 189 subjects in Phase I of the study who received at least 1 Sham Device and the 170 subjects in Phase II who were followed after balloon removal</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Chiari Malformation</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcer disease</sub_title>
                <description>Device or Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Heel Exostosis</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bacterial Meningitis</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Pap Smear</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Synovectomy</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <description>NOT Device or Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 244/336 (76.62%) / 494 Events</description>
                <counts group_id="E1" events="501" subjects_affected="246" subjects_at_risk="336"/>
                <counts group_id="E2" events="65" subjects_affected="51" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 188/336 (55.95%) / 311 Events</description>
                <counts group_id="E1" events="315" subjects_affected="191" subjects_at_risk="336"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 58/336 (17.26%) / 71 Events</description>
                <counts group_id="E1" events="75" subjects_affected="61" subjects_at_risk="336"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 57/336 (16.96%) / 69 Events</description>
                <counts group_id="E1" events="73" subjects_affected="60" subjects_at_risk="336"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 49/336 (14.58%) / 54 Events</description>
                <counts group_id="E1" events="54" subjects_affected="49" subjects_at_risk="336"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 31/336 (9.23%) / 37 Events</description>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 28/336 (8.33%) / 30 Events</description>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="336"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastric Irritation</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 24/336 (7.14%) / 25 Events</description>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastric Bleeding/Abrasion</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 17/336 (5.06%) / 17 Events</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 9/336 (2.68%) / 10 Events</description>
                <counts group_id="E1" events="57" subjects_affected="51" subjects_at_risk="336"/>
                <counts group_id="E2" events="47" subjects_affected="37" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common Cold/Upper Respiratory Infection</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 0/336 (0.00%) / 0 Events</description>
                <counts group_id="E1" events="56" subjects_affected="46" subjects_at_risk="336"/>
                <counts group_id="E2" events="50" subjects_affected="44" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Stomach/Seasonal Flu</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 0/336 (0.00%) / 0 Events</description>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="336"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Headache/Migraine</sub_title>
                <description>Treated Subjects - Device or Procedure Related Only (FDA Reviewed): 6/336 (1.79%) / 7 Events</description>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="336"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy VandenBerg, Vice-President, Clinical Affairs and Regulatory Affairs</name_or_title>
      <organization>Obalon Therapeutics, Inc.</organization>
      <phone>760.795.6551</phone>
      <email>avandenberg@obalon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

